ADVISORY, Dec. 18, 2013 (GLOBE NEWSWIRE) -- What: TetraLogic Pharmaceuticals Corporation [TLOG], a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics called SMAC-mimetics for the treatment of cancers and viral diseases, will visit the NASDAQ MarketSite in Times Square in celebration of its recent initial public offering (IPO) which occurred on Thursday, December 12, 2013. In honor of the occasion, J. Kevin Buchi, TetraLogic's President and Chief Executive Officer, will ring the Opening Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Thursday, December 19, 2013 – 9:15 a.m. to 9:30 a.m. ET Contact: Pete A. Meyers Chief Financial Officer (610) 889-9900, x103 Pete.Meyers@tetralogicpharma.com NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ. For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx. Webcast: A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx. Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice. About TetraLogic Pharmaceuticals Corporation [TLOG]: TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, our clinical-stage product candidate, is currently being tested in Phase 1 and Phase 2 oncology clinical trials for hematological malignancies and multiple solid tumors.